Golimumab: clinical update on its use for ulcerative colitis
D Gilardi1, G Fiorino1, M Allocca1
1IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Drugs of Today (Barcelona, Spain : 1998)
|April 17, 2015
Summary
New biologic therapy, golimumab, offers a promising treatment option for moderate to severe ulcerative colitis. This anti-tumor necrosis factor alpha agent demonstrates efficacy and safety comparable to existing therapies for inflammatory bowel disease.
Area of Science:
- Gastroenterology and immunology
- Pharmacology of biologic agents
Background:
- Biologic therapies targeting tumor necrosis factor alpha (anti-TNF-α) have transformed inflammatory bowel disease (IBD) management.
- Ulcerative colitis (UC) and Crohn's disease are chronic IBDs requiring effective treatment strategies.
Purpose of the Study:
- To review the efficacy and safety of golimumab, a novel anti-TNF-α agent.
- To provide an overview of golimumab's role in treating moderate to severe ulcerative colitis.
Main Methods:
- Review of preclinical and clinical studies on golimumab.
- Comparison of golimumab's profile with other anti-TNF-α agents like infliximab and adalimumab.
Main Results:
- Golimumab has been approved for moderate to severe ulcerative colitis treatment.
- Preclinical and clinical data support golimumab's efficacy.
- Golimumab exhibits an efficacy and safety profile consistent with established anti-TNF-α therapies.
Conclusions:
- Golimumab represents a valuable new therapeutic option for patients with moderate to severe ulcerative colitis.
- The drug's performance aligns with existing anti-TNF-α treatments, offering a comparable risk-benefit ratio.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
01:29Inflammatory Bowel Disease IV: Pharmacological Management
989
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
989
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
716
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
716
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
804
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
682
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
682
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K